ProtoKinetix, Incorporated (PKTX)
USD 0.01
(-16.79%)
USD 0.01
(-16.79%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 480.55 Thousand USD | 3.82% |
| 2022 | 462.87 Thousand USD | 3.73% |
| 2021 | 446.23 Thousand USD | -4.89% |
| 2020 | 469.18 Thousand USD | -19.92% |
| 2019 | 585.9 Thousand USD | 80.36% |
| 2018 | 324.85 Thousand USD | -37.3% |
| 2017 | 518.09 Thousand USD | -4.43% |
| 2016 | 542.09 Thousand USD | 20.53% |
| 2015 | 449.75 Thousand USD | 7635.67% |
| 2014 | 5814.00 USD | -76.41% |
| 2013 | 24.64 Thousand USD | 192.49% |
| 2012 | 8426.00 USD | -71.7% |
| 2011 | 29.77 Thousand USD | -56.96% |
| 2010 | 69.17 Thousand USD | -73.74% |
| 2009 | 263.41 Thousand USD | 2.41% |
| 2008 | 257.22 Thousand USD | 74.06% |
| 2007 | 147.77 Thousand USD | -75.93% |
| 2006 | 613.95 Thousand USD | -80.94% |
| 2005 | 3.22 Million USD | -12.09% |
| 2004 | 3.66 Million USD | 52.69% |
| 2003 | 2.4 Million USD | 414425.73% |
| 2002 | 579.00 USD | -83.52% |
| 2001 | 3513.00 USD | -31.98% |
| 2000 | 5165.00 USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 461.4 Thousand USD | -3.99% |
| 2024 Q2 | 473.52 Thousand USD | 2.63% |
| 2023 Q1 | 447.3 Thousand USD | -3.36% |
| 2023 Q2 | 466.98 Thousand USD | 4.4% |
| 2023 FY | 480.55 Thousand USD | 3.82% |
| 2023 Q3 | 450.89 Thousand USD | -3.44% |
| 2023 Q4 | 480.55 Thousand USD | 6.58% |
| 2022 Q2 | 413.04 Thousand USD | -3.37% |
| 2022 FY | 462.87 Thousand USD | 3.73% |
| 2022 Q1 | 427.42 Thousand USD | -4.21% |
| 2022 Q3 | 479.73 Thousand USD | 16.15% |
| 2022 Q4 | 462.87 Thousand USD | -3.52% |
| 2021 FY | 446.23 Thousand USD | -4.89% |
| 2021 Q3 | 485.76 Thousand USD | 19.8% |
| 2021 Q4 | 446.23 Thousand USD | -8.14% |
| 2021 Q1 | 560.42 Thousand USD | 19.45% |
| 2021 Q2 | 405.47 Thousand USD | -27.65% |
| 2020 FY | 469.18 Thousand USD | -19.92% |
| 2020 Q3 | 296.45 Thousand USD | 3.12% |
| 2020 Q4 | 469.18 Thousand USD | 58.27% |
| 2020 Q2 | 287.49 Thousand USD | 4.55% |
| 2020 Q1 | 274.97 Thousand USD | -53.07% |
| 2019 Q4 | 585.9 Thousand USD | 18.99% |
| 2019 Q3 | 492.38 Thousand USD | -33.65% |
| 2019 Q1 | 234.76 Thousand USD | -27.73% |
| 2019 FY | 585.9 Thousand USD | 80.36% |
| 2019 Q2 | 742.09 Thousand USD | 216.1% |
| 2018 Q2 | 438 Thousand USD | 7.88% |
| 2018 Q1 | 406 Thousand USD | -21.64% |
| 2018 FY | 324.85 Thousand USD | -37.3% |
| 2018 Q4 | 324.85 Thousand USD | 8.17% |
| 2018 Q3 | 300.3 Thousand USD | -31.44% |
| 2017 Q4 | 518.09 Thousand USD | -18.75% |
| 2017 FY | 518.09 Thousand USD | -4.43% |
| 2017 Q3 | 637.64 Thousand USD | 19.87% |
| 2017 Q2 | 531.95 Thousand USD | -25.94% |
| 2017 Q1 | 718.26 Thousand USD | 32.5% |
| 2016 Q3 | 255.99 Thousand USD | -26.11% |
| 2016 Q1 | 340.55 Thousand USD | -24.28% |
| 2016 FY | 542.09 Thousand USD | 20.53% |
| 2016 Q4 | 542.09 Thousand USD | 111.76% |
| 2016 Q2 | 346.42 Thousand USD | 1.72% |
| 2015 Q4 | 449.75 Thousand USD | 89.65% |
| 2015 Q3 | 237.14 Thousand USD | 26.02% |
| 2015 Q2 | 188.17 Thousand USD | 11.99% |
| 2015 Q1 | 168.03 Thousand USD | 2790.16% |
| 2015 FY | 449.75 Thousand USD | 7635.67% |
| 2014 Q1 | 5428.00 USD | -77.98% |
| 2014 FY | 5814.00 USD | -76.41% |
| 2014 Q4 | 5814.00 USD | -61.15% |
| 2014 Q3 | 14.96 Thousand USD | 49.69% |
| 2014 Q2 | 9997.00 USD | 84.17% |
| 2013 Q3 | 16.11 Thousand USD | -30.17% |
| 2013 Q2 | 23.08 Thousand USD | 5.46% |
| 2013 Q1 | 21.88 Thousand USD | 159.73% |
| 2013 FY | 24.64 Thousand USD | 192.49% |
| 2013 Q4 | 24.64 Thousand USD | 52.92% |
| 2012 Q2 | 19.68 Thousand USD | -0.87% |
| 2012 Q3 | 9998.00 USD | -49.2% |
| 2012 FY | 8426.00 USD | -71.7% |
| 2012 Q4 | 8426.00 USD | -15.72% |
| 2012 Q1 | 19.85 Thousand USD | -33.32% |
| 2011 FY | 29.77 Thousand USD | -56.96% |
| 2011 Q4 | 29.77 Thousand USD | -42.26% |
| 2011 Q3 | 51.56 Thousand USD | 236.27% |
| 2011 Q2 | 15.33 Thousand USD | -30.25% |
| 2011 Q1 | 21.98 Thousand USD | -68.22% |
| 2010 Q1 | 304.02 Thousand USD | 15.42% |
| 2010 FY | 69.17 Thousand USD | -73.74% |
| 2010 Q4 | 69.17 Thousand USD | -61.44% |
| 2010 Q3 | 179.37 Thousand USD | -31.16% |
| 2010 Q2 | 260.56 Thousand USD | -14.29% |
| 2009 Q4 | 263.41 Thousand USD | -12.5% |
| 2009 Q2 | 335.85 Thousand USD | 78.25% |
| 2009 Q1 | 188.41 Thousand USD | -26.75% |
| 2009 FY | 263.41 Thousand USD | 2.41% |
| 2009 Q3 | 301.04 Thousand USD | -10.37% |
| 2008 FY | 257.22 Thousand USD | 74.06% |
| 2008 Q4 | 257.22 Thousand USD | 2.36% |
| 2008 Q3 | 251.28 Thousand USD | -50.27% |
| 2008 Q2 | 505.28 Thousand USD | 99.04% |
| 2008 Q1 | 253.85 Thousand USD | 71.78% |
| 2007 FY | 147.77 Thousand USD | -75.93% |
| 2007 Q3 | 303.61 Thousand USD | -20.47% |
| 2007 Q4 | 147.77 Thousand USD | -51.33% |
| 2007 Q2 | 381.74 Thousand USD | -25.34% |
| 2007 Q1 | 511.34 Thousand USD | -16.71% |
| 2006 FY | 613.95 Thousand USD | -80.94% |
| 2006 Q2 | 3.48 Million USD | -3.02% |
| 2006 Q3 | 3.38 Million USD | -2.86% |
| 2006 Q4 | 613.95 Thousand USD | -81.89% |
| 2006 Q1 | 3.59 Million USD | 11.67% |
| 2005 Q3 | 3.54 Million USD | -4.6% |
| 2005 FY | 3.22 Million USD | -12.09% |
| 2005 Q4 | 3.22 Million USD | -9.02% |
| 2005 Q2 | 3.71 Million USD | -0.24% |
| 2005 Q1 | 3.72 Million USD | 1.54% |
| 2004 Q3 | 2.48 Million USD | -0.42% |
| 2004 Q1 | 2.65 Million USD | 10.78% |
| 2004 Q2 | 2.49 Million USD | -6.09% |
| 2004 Q4 | 3.66 Million USD | 47.38% |
| 2004 FY | 3.66 Million USD | 52.69% |
| 2003 Q4 | 2.4 Million USD | 364103.95% |
| 2003 Q3 | 659.00 USD | 0.0% |
| 2003 FY | 2.4 Million USD | 414425.73% |
| 2003 Q2 | 659.00 USD | 0.0% |
| 2002 FY | 579.00 USD | -83.52% |
| 2002 Q1 | - USD | 0.0% |
| 2001 Q3 | - USD | 0.0% |
| 2001 FY | 3513.00 USD | -31.98% |
| 2000 FY | 5165.00 USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 2310.00 USD | -20703.333% |
| Arch Therapeutics, Inc. | 1.95 Million USD | 75.459% |
| Evofem Biosciences, Inc. | 10.55 Million USD | 95.447% |
| Nascent Biotech, Inc. | 552.12 Thousand USD | 12.961% |
| Rebus Holdings, Inc. | 5000.00 USD | -9511.14% |
| Santhera Pharmaceuticals Holding AG | 130.21 Million USD | 99.631% |
| Qrons Inc. | 420.00 USD | -114318.333% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 770.64 Thousand USD | 37.642% |
| Northwest Biotherapeutics, Inc. | 27.94 Million USD | 98.28% |
| Skye Bioscience, Inc. | 11.94 Million USD | 95.975% |
| Eiger BioPharmaceuticals, Inc. | 38.84 Million USD | 98.763% |
| Nanobac Pharmaceuticals, Incorporated | 7.21 Million USD | 93.344% |
| Institute of Biomedical Research Corp. | 76.35 Thousand USD | -529.38% |
| SQZ Biotechnologies Company | 107.18 Million USD | 99.552% |
| Intellipharmaceutics International Inc. | 1.43 Million USD | 66.442% |
| Propanc Biopharma, Inc. | 72.36 Thousand USD | -564.074% |
| Mesoblast Limited | 667.9 Million USD | 99.928% |
| Marizyme, Inc. | 22.01 Million USD | 97.817% |
| Genus plc | 1.02 Billion USD | 99.953% |
| VioQuest Pharmaceuticals, Inc. | 1.35 Million USD | 64.622% |
| Pharming Group N.V. | 462.85 Million USD | 99.896% |
| Therapeutic Solutions International, Inc. | 3.31 Million USD | 85.495% |
| CNBX Pharmaceuticals Inc. | 499.03 Thousand USD | 3.704% |
| Nymox Pharmaceutical Corporation | 627 Thousand USD | 23.356% |
| ContraFect Corporation | 20.67 Million USD | 97.676% |
| PsyBio Therapeutics Corp. | 390.36 Thousand USD | -23.104% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 382.17 Thousand USD | -25.742% |
| IMV Inc. | 31.33 Million USD | 98.466% |
| AXIM Biotechnologies, Inc. | 4.14 Million USD | 88.409% |
| MultiCell Technologies, Inc. | 126.22 USD | -380629.678% |
| ONE Bio Corp. | 70.08 Million USD | 99.314% |
| Accustem Sciences Inc. | 939.68 Thousand USD | 48.86% |
| RVL Pharmaceuticals plc | 128.51 Million USD | 99.626% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 431.71 Thousand USD | -11.314% |
| Q BioMed Inc. | 3.51 Million USD | 86.33% |
| Emmaus Life Sciences, Inc. | 35.17 Million USD | 98.634% |
| Mosaic ImmunoEngineering Inc. | 261.27 Thousand USD | -83.926% |
| Biomind Labs Inc. | 73.81 Thousand USD | -550.994% |
| American Oriental Bioengineering, Inc. | 446.3 Million USD | 99.892% |
| Provectus Biopharmaceuticals, Inc. | 1.44 Million USD | 66.832% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 30.01 Million USD | 98.399% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| THC Farmaceuticals, Inc. | 2.74 Million USD | 82.502% |
| Acro Biomedical Co., Ltd. | 687.48 Thousand USD | 30.099% |
| Curative Biotechnology, Inc. | 2.6 Million USD | 81.54% |
| GB Sciences, Inc. | 103.44 Thousand USD | -364.567% |
| Alpha Cognition Inc. | 2.45 Million USD | 80.403% |
| HST Global, Inc. | 1526.00 USD | -31391.284% |
| CSL Limited | 38.02 Billion USD | 99.999% |
| Wesana Health Holdings Inc. | 987.96 Thousand USD | 51.359% |
| Halberd Corporation | 10.13 Thousand USD | -4643.431% |
| Enzolytics Inc. | 361.7 Million USD | 99.867% |
| Agentix Corp. | 261.39 Thousand USD | -83.845% |
| Resverlogix Corp. | 8.11 Million USD | 94.078% |
| Nuo Therapeutics, Inc. | 1.87 Million USD | 74.41% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 4.54 Billion USD | 99.989% |
| Enzon Pharmaceuticals, Inc. | 47.7 Million USD | 98.993% |
| Endonovo Therapeutics, Inc. | 639.65 Thousand USD | 24.873% |
| RespireRx Pharmaceuticals Inc. | 22.78 Thousand USD | -2009.464% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 8.94 Million USD | 94.63% |
| AVAX Technologies, Inc. | 7.37 Million USD | 93.486% |
| Zenith Capital Corp. | 7410.00 USD | -6385.25% |
| Genscript Biotech Corporation | 3.38 Billion USD | 99.986% |
| Ember Therapeutics, Inc. | 184.00 USD | -261072.283% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 321.8 Thousand USD | -49.331% |
| WPD Pharmaceuticals Inc. | 261.36 Thousand USD | -83.865% |
| Cotinga Pharmaceuticals Inc. | 927.96 Thousand USD | 48.214% |
| Kadimastem Ltd | 2.3 Million USD | 79.143% |
| Helix BioMedix, Inc. | 3.02 Million USD | 84.114% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 52.7 Million USD | 99.088% |
| BioStem Technologies, Inc. | 14.56 Million USD | 96.7% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 57.09 Thousand USD | -741.694% |
| LadRx Corporation | 2.3 Million USD | 79.178% |
| Cell Source, Inc. | 195.17 Thousand USD | -146.224% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -35.898% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -35.898% |
| NovAccess Global Inc. | 62.24 Thousand USD | -672.004% |
| Affymax, Inc. | 7.44 Million USD | 93.544% |
| Itoco Inc. | 1.4 Million USD | 65.676% |
| Rasna Therapeutics, Inc. | 95.65 Thousand USD | -402.375% |
| Pathfinder Cell Therapy, Inc. | 106 Thousand USD | -353.356% |
| Mobile Lads Corp. | 52.00 USD | -924048.077% |
| CytoDyn Inc. | 11.13 Million USD | 95.685% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 142.97 Thousand USD | -236.12% |
| NanoSphere Health Sciences Inc. | 17.88 Thousand USD | -2587.679% |
| Alseres Pharmaceuticals, Inc. | 385.47 Thousand USD | -24.667% |
| SYBLEU INC | 330.46 Thousand USD | -45.417% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 409.42 Thousand USD | -17.374% |
| International Stem Cell Corporation | 5.39 Million USD | 91.084% |
| Bioxytran, Inc. | 137.63 Thousand USD | -249.146% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 15 Million USD | 96.797% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 16.57 Million USD | 97.101% |
| Adhera Therapeutics, Inc. | 79 Thousand USD | -508.3% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 864.67 Thousand USD | 44.424% |
| Innovation Pharmaceuticals Inc. | 7.51 Million USD | 93.607% |
| Neutra Corp. | 2851.00 USD | -16755.735% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | 98.517% |
| PureTech Health plc | 693.97 Million USD | 99.931% |
| Coeptis Therapeutics, Inc. | 8.07 Million USD | 94.046% |
| IXICO plc | 15.84 Million USD | 96.967% |
| IntelGenx Technologies Corp. | 8.28 Million USD | 94.198% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 99.535% |
| CSL Limited | 38.02 Billion USD | 99.999% |
| Cellectis S.A. | 333.99 Million USD | 99.856% |